Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01964807 · ClinicalTrials.gov registry record · NA
Cardiovascular Assessment of the Effects of Tobacco and Nicotine Delivery Products
A NA study, sponsored by University of California, San Francisco.
- Completed
- Registry status
- NA
- Development phase
- 81
- Enrollment target
NCT01964807: Completed NA study, sponsored by University of California, San Francisco.
NCT01964807 is a NA study that has completed, run by University of California, San Francisco. The registered enrollment target is 81 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (94% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01964807, a NA study, has completed, sponsored by University of California, San Francisco.
- COMPLETED
- Registry status
- NA
- Development phase
- 81 participants
- Enrollment target
Study Summary
The overarching goal of this project is to develop a panel of cardiovascular risk biomarkers that can detect differences in the cardiovascular safety of various tobacco products, whether conventional, new or emerging, in order to help the FDA with the task of regulating them. This will be achieved through 4 aims: Aim 1: Determine the relative contributions of nicotine and combustion products to the cardiovascular risk of active cigarette smoking. Aim 2: Determine which cardiovascular risk biomarkers are affected by exposure to secondhand smoke. Aim 3: Determine the cardiovascular risk of smokeless tobacco use. Aim 4: Determine the cardiovascular risk of electronic cigarettes and the respective contributions of nicotine and electronic cigarette vapor.
Primary Outcome
Vascular function as measured by Flow-mediated Dilation of the Brachial Artery
Interventions
- OTHER Cigarette, NIDA test type with 16.6 mg nicotine
- OTHER Cigarette, NIDA test type with <0.45 mg nicotine
- OTHER Electronic cigarette with 18 mg/ml nicotine
- OTHER Electronic Cigarette with no nicotine
- OTHER Moist snuff
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 81 participants |
| Start Date | 2013-11-03 |
| Est. Completion | 2021-05-31 |
| Phase | NA |
What the finished NCT01964807 record still lists
NCT01964807 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 81 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (94% lower).
The record links to 0 conditions, and to 5 interventions - of which Cigarette, NIDA test type with 16.6 mg nicotine is the first listed.
NCT01964807 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01964807 about?
NCT01964807 is a clinical study titled "Cardiovascular Assessment of the Effects of Tobacco and Nicotine Delivery Products". The overarching goal of this project is to develop a panel of cardiovascular risk biomarkers that can detect differences in the cardiovascular safety of various tobacco products, whether conventional, new or emerging, in order to help the FDA with the task of regulating them. This will be achieved t...
What is the current status of trial NCT01964807?
This trial is currently completed. It is a NA study. The enrollment target is 81 participants. The study started on 2013-11-03. Estimated completion is 2021-05-31.
What interventions are being tested in trial NCT01964807?
The interventions under investigation include: Cigarette, NIDA test type with 16.6 mg nicotine (OTHER), Cigarette, NIDA test type with <0.45 mg nicotine (OTHER), Electronic cigarette with 18 mg/ml nicotine (OTHER), Electronic Cigarette with no nicotine (OTHER), Moist snuff (OTHER).
Who is sponsoring clinical trial NCT01964807?
This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01964807's enrollment target sits among peer trials
81 992nd of 2000 higher than 1,007 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04966481 · 81 participants · Phase 3
Palbociclib and Cetuximab Versus Cetuximab Monotherapy for Patients With CDKN2A-altered, HPV-unrelated Head and Neck Squamous Cell Carcinoma Who Experienced Disease Progression on a PD-1/L1 Inhibitor
- NCT05109429 · 81 participants · NA
Developing a Clinical Outcome Assessment for Opioid Craving
- NCT05112601 · 81 participants · Phase 2
Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma
- NCT05305911 · 81 participants · Phase 2
Sodium Glucose Co-Transporter 2 (SGLT2) and STEMI
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI